DaVita Inc. (NYSE:DVA) Stake Reduced by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP trimmed its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 7.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 902,418 shares of the company's stock after selling 76,859 shares during the period. Dimensional Fund Advisors LP owned 1.10% of DaVita worth $134,959,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. Epoch Investment Partners Inc. purchased a new position in shares of DaVita in the 4th quarter worth approximately $55,100,000. Invesco Ltd. boosted its position in DaVita by 20.9% during the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock valued at $237,716,000 after purchasing an additional 275,284 shares in the last quarter. Amundi lifted its position in DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after acquiring an additional 240,126 shares during the last quarter. Bridgewater Associates LP lifted its holdings in shares of DaVita by 298.4% during the 4th quarter. Bridgewater Associates LP now owns 239,970 shares of the company's stock valued at $35,888,000 after purchasing an additional 179,744 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ grew its stake in shares of DaVita by 256.8% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company's stock worth $24,301,000 after acquiring an additional 116,758 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DVA has been the topic of several research reports. Barclays increased their price target on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Sanford C. Bernstein set a $184.00 target price on DaVita in a report on Friday, February 21st. Finally, Cowen restated a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $166.33.

DaVita Price Performance

Shares of DaVita stock traded down $0.20 during trading on Thursday, reaching $141.35. The company's stock had a trading volume of 172,570 shares, compared to its average volume of 835,781. The business has a 50 day moving average price of $146.11 and a 200-day moving average price of $154.92. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The company has a market capitalization of $11.31 billion, a P/E ratio of 13.19, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04. DaVita Inc. has a 12-month low of $131.27 and a 12-month high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, sell-side analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.